Month: July 2016

July 29, 2016
Emicizumab data looks encouraging

29 July 2016 Emicizumab, the humanized bispecific monoclonal antibody, in development by Roche/Genentech, continues to look promising for people with severe hemophilia A, with or without inhibitors to factor VIII. The Phase 1/2 data released at WFH in Orlando assessed emicizumab in an extension of a 21 to 32-month period which included Japanese patients with …

Read article